## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (currently amended) At least one chemical ontity chosen from compounds A compound of Formula (I):

wherein:

A represents hydroxy;

R¹ represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, each of which may be optionally substituted by one or more substituents selected from  $-C_{1-6}$ alkyl, halo,  $-OR^A$ ,  $-SR^A$ ,  $-C(O)NR^BR^C$ ,  $-C(O)R^D$ ,  $-CO_2H$ ,  $-CO_2R^D$ ,  $-NR^BR^C$ ,  $-NR^EC(O)R^D$ ,  $-NR^ECO_2R^D$ ,  $-NR^EC(O)NR^FR^G$ ,  $-SO_2NR^FR^G$ ,  $-SO_2R^D$ , nitro, cyano,  $-CF_3$ ,  $-OCF_3$ ,  $NR^ESO_2R^D$ , phenyl and heterocyclyl, wherein the  $-C_{1-6}$ alkyl substituent itself may be optionally substituted by one or more substituents selected from  $-C_{5-9}$ cycloalkyl, halo,  $-NR^BR^C$ ,  $-C(O)NR^BR^C$ ,  $-NR^EC(O)R^D$ ,  $-SR^A$ ,  $-SO_2R^D$ ,  $OR^A$ , oxo, phenyl, heteroaryl or heterocyclyl; or R¹ represents  $-C_{1-6}$ alkyl or  $-C_{5-9}$ cycloalkyl;

 $R^2$  represents phenyl substituted by one or more substituents selected from -C<sub>1</sub>.  $_{\$}$ alkyl, halo, -OR<sup>A</sup>, -SR<sup>A</sup>, -C(O)NR<sup>B</sup>R<sup>C</sup>, -C(O)R<sup>D</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>D</sup>, -NR<sup>B</sup>R<sup>C</sup>, -NR<sup>E</sup>C(O)R<sup>D</sup>, -NR<sup>E</sup>CO<sub>2</sub>R<sup>D</sup>, -NR<sup>E</sup>C(O)NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>R<sup>D</sup>, nitro, cyano, and heterocyclyl; or R<sup>2</sup> represents -(CH<sub>2</sub>)<sub>n</sub>C<sub>5-7</sub>cycloalkyl optionally substituted on the cycloalkyl by one or more substitutents selected from -C<sub>1-8</sub>alkyl, =CH(CH<sub>2</sub>)<sub>1</sub>H, -OR<sup>A</sup>, -SR<sup>A</sup>, -C(O)NR<sup>B</sup>R<sup>C</sup>, -C(O)R<sup>D</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>D</sup>, -NR<sup>B</sup>R<sup>C</sup>, -NR<sup>E</sup>C(O)R<sup>D</sup>, -NR<sup>E</sup>CO<sub>2</sub>R<sup>D</sup>, -NR<sup>E</sup>C(O)NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>R<sup>D</sup>, fluoro, nitro, cyano, oxo, and heterocyclyl, or wherein two substituents may together form a C<sub>1-2</sub>alkylene bridge substituent;

t represents 0, 1, 2, 3 or 4;

n represents 0 or 1;

 $R^3$  represents heterocyclyl or heteroaryl; or phenyl optionally substituted by one or more substituents selected from -C<sub>1-8</sub>alkyl, halo, -OR<sup>A</sup>, -SR<sup>A</sup>, -C(O)NR<sup>B</sup>R<sup>C</sup>, -C(O)R<sup>D</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>D</sup>, -NR<sup>B</sup>C<sup>C</sup>, -NR<sup>E</sup>C(O)R<sup>D</sup>, -NR<sup>E</sup>CO<sub>2</sub>R<sup>D</sup>, -NR<sup>E</sup>C(O)NR<sup>E</sup>R<sup>G</sup>, -SO<sub>2</sub>NR<sup>E</sup>R<sup>G</sup>, -SO<sub>2</sub>NR<sup>E</sup>R<sup>G</sup>, -SO<sub>2</sub>R<sup>D</sup>, nitro, cyano, and heterocyclyl; or R<sup>3</sup> represents -C<sub>1-8</sub>alkyl optionally substituted by one or more substituents selected from -C<sub>1-8</sub>alkyl, -OR<sup>A</sup>, -SR<sup>A</sup>, -C(O)NR<sup>B</sup>R<sup>C</sup>, -C(O)R<sup>D</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>D</sup>, -NR<sup>E</sup>C(O)R<sup>D</sup>, -NR<sup>E</sup>CO<sub>2</sub>R<sup>D</sup>, -NR<sup>E</sup>C(O)NR<sup>E</sup>R<sup>G</sup>, -SO<sub>2</sub>NR<sup>E</sup>R<sup>G</sup>, -SO<sub>2</sub>R<sup>D</sup>, fluoro, nitro, cyano, oxo, phenyl, heteroaryl and heterocyclyl;

R<sup>4</sup> represents hydrogen;

R<sup>A</sup> represents hydrogen, -C<sub>1-8</sub>alkyl, arylalkyl, heteroarylalkyl, aryl, heterocyclyl or heteroaryl;

 $R^B$  and  $R^C$  independently represent hydrogen, -C<sub>1-6</sub>alkyl, aryl, heterocyclyl or heteroaryl; or  $R^B$  and  $R^C$  together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

 $R^D$  is selected from the group consisting of -C<sub>1-8</sub>alkyl, aryl, heterocyclyl, heteroaryl, arylalkyl, and heteroarylalkyl;

R<sup>E</sup> represents hydrogen or -C<sub>1-e</sub>alkyl;

R<sup>F</sup> and R<sup>G</sup> are independently selected from the group consisting of hydrogen, -C<sub>1</sub>. salkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or R<sup>F</sup> and R<sup>G</sup> together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

and salts, solvates and esters or a pharmaceutically acceptable salt, solvate or ester thereof.

SEP. 26. 2006 2:16PM

3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-phenyl-1*H*-pyrazole-4-carboxylic acid:

3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(4-methylphenyl)-1H-pyrazole-4-carboxylic acid;

1-(1-Cyclohexen-1-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-(4-Chloro-3-methylphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-(4-Fluorophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-(6-Indolyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-(4-Hydroxyphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylic acid;

1-[4-(Acetylamino)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-(4-Biphenylyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-[4-(Dimethylamino)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(methyloxy)phenyl]-1H-pyrazole-4-carboxylic acid;

1-(4-Acetylphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(trifluoromethyl)oxy]phenyl}-1H-pyrazole-4-carboxylic acid;

1-(4-Cyanophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

1-{4-[(Dimethylamino)carbonyl]phenyl}-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(3-thienyl)-1H-pyrazole-4-carboxylic acid;

- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[3-(trifluoromethyl)phenyl]-1H-pyrazole-4-carboxylic acid;
- 1-(3,5-Dimethylphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3-Chloro-5-fluorophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[3,5-Bis(trifluoromethyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(1,3-Benzodioxol-5-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(2,3-Dihydro-1-benzofuran-5-yl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(3,4,5-trifluorophenyl)-1H-pyrazole-4-carboxylic acid;
- 1-(4-Chlorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[3-(methyloxy)phenyl]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(methylsulfonyl)phenyl]-1H-pyrazole-4-carboxylic acid;
- 1-(2-Fluorophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3-Hydroxyphenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(3-methylphenyl)-1H-pyrazole-4-carboxylic acid;
- 1-(3-Fluorophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(4-Aminophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3-Chlorophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{3-[(trifluoromethyl)oxy]phenyl}-1H-pyrazole-4-carboxylic acid;

- 1-(4-Chloro-3-fluorophenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3-Amino-4-methylphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3-Fluoro-4-methylphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3,4-Difluorophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[(E)-1-Hexen-1-yl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[(E)-2-Cyclohexylethenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[(E)-4-methyl-1-penten-1-yl]-1H-pyrazole-4-carboxylic acid;
- 1-[(E)-2-(4-Fluorophenyl)ethenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(4-Ethenylphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-(Hydroxymethyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(4-Ethylphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(1-methylethyl)phenyl]-1H-pyrazole-4-carboxylic acid;
- 1-(5-Acetyl-2-thienyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(5-Chloro-2-thienyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(5-methyl-2-thienyl)-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-(5-phenyl-2-thienyl)-1H-pyrazole-4-carboxylic acid;
- 1-((4-Methyl)cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(6-Benzofuranyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

- 1-(Cyclohepten-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-((4-Methyl)cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-(methylsulfonyl)-4-piperidinyl]amino]-1H-pyrazole-4-carboxylic acid;
- 1-((4,4-Dimethyl)cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3-Chloro-4-benzyloxyphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(4-Benzyloxy-cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1)-1H-pyrazole-4-carboxylic acid;
- 1-(4,4-Dimethyl)cyclohexen-1-yl)-3-{[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(Ε)-2-phenylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(Z)-2-phenylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4[(Z)-2-(3-pyrazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4[(E)-2-(3-pyrazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4[(E)-2-( tetrahydro-2H-pyran-4-yl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(E)-2-(4-thiazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(Z)-2-(4-thiazolyl)-ethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 1-((E)-2-tert-Butyl-ethenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-((E)-2-Phenyl-ethenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(4-Methyl-1-cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-(3-Cyanophenyl)-3-[[(*trans*-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-{(1-Methylethyl)[(4-methylidenecyclohexyl)carbonyl]amino}-1-phenyl-1*H*-pyrazole-4-carboxylic acid;

- 1-(4-Trifluoromethyl-cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-

[(phenyloxy)methyl] phenyl}-1H-pyrazole-4-carboxylic acid;

- 1-[4-(Phenylsulfonylmethyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-(Phenylthiomethyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-(Phenoxy)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-{(1,3-Thiazol-4-ylmethyl)oxy}phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-([E]-Phenylethenyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-[Z]-Phenylethenyl))phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-([E,Z]-(1,3-Thiazol-2-yl)ethenyl)phenyl]-3-[[(trans-4-

methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;

- 1-[4-([E]-Phenyl-2-methylethenyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-[E]-(Pyridin-4-yl)ethenyl))phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-([E]-(1,3-Thiazol-4-yl)ethenyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-([E]-(Furan-2-yl)ethenyl))phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 1-[4-([E]-(2-Methyl-1,3-thiazol-4-yl)ethenyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[(Cyclohexylacetyl)(1-methylethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-{(1-Methylethyl)[(4-methylphenyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-[[(4-Bromo-2-chlorophenyl)carbonyl](1-methylethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](phenyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-{[2-(Dimethylamino)-2-oxoethyl][(trans-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;

- 3-([(trans-4-Methylcyclohexyl)carbonyl]{1-[(methyloxy)carbonyl]-4-piperidinyl}amino)-
- 1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-{[(trans-4-Methylcyclohexyl)carbonyl][1-(methylsulfonyl)-4-piperidinyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methyl-4-piperidinyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-{{1-[(Ethylamino)carbonyl]-4-piperidinyl}[(trans-4-
- methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](2-pyrazinylmethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
- *rel-*3-[{[(1\$,2R,4\$)-2-Hydroxy-4-methylcyclohexyl]carbonyl}(1-methylethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-[(3-methoxyphenylcarbonyl)amino]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(phenylmethyl)oxy]phenyl}-1H-pyrazole-4-carboxylic acid;
- 1-(1H-Indol-5-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(E/Z)-2-phenylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-(2-phenylethyl)phenyl]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[2-phenylethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-[(1,3-thiazol-4-yl)-ethyl]phenyl]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-{4-[(1,3-thiazol-4-yl)-ethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
- 1-Cyclohexyl-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[1-(methylsulfonyl)-
- 1,2,3,6-tetrahydro-4-pyridinyl]-1H-pyrazole-4-carboxylic acid;
- 3-[[(trans-4-Methylcyclohexyl)carbonyl](phenylmethyl)amino]-1-phenyl-1H-pyrazole-4-carboxylic acid;
- 3-{Cyclopentyl[(trans-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-pyrazole-4-carboxylic acid;

```
3-[[(trans-4-Methylcyclohexyl)carbonyl](tetrahydro-2H-pyran-4-yl)amino]-1-phenyl-
1H-pyrazole-4-carboxylic acid;
3-{(1-Acetyl-4-piperidinyl)[(trans-4-methylcyclohexyl)carbonyl]amino}-1-phenyl-1H-
pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](4-piperidinyl)amino]-1-phenyl-1H-pyrazole-4-
carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(E)-2-
cyclohexylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
1-[4-(2-Cyclohexylethyl)phenyl]-3-[[(trans-4-methylcyclohexyl)carbonyl](1-
methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-[4-[2-
pyridinylethenyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[2-
pyridinylethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[1,3-thiazol-2-
ylethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[2-(1H-pyrazol-3-
yl)ethyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-
[(phenylamino)carbonyl]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-
[(phenylcarbonyl)amino]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(3-
methylphenylcarbonyl)amino[phenyl]-1H-pyrazole-4-carboxylic acid;
3-([(trans-4-Methylcyclohexyl)carbonyl]{1-[(tert-butyloxy)carbonyl]-4-
piperidinyl}amino)-1-phenyl-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-[(4-
fluorophenylcarbonyl)amino]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-
[(cyclohexylcarbonyl)amino]phenyl}-1H-pyrazole-4-carboxylic acid;
1-(4-{[(4-Fluorophenyl)amino]carbonyl}phenyl)-3-[[(trans-4-
methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{3-
[(chlorophenylcarbonyl)amino]phenyl}-1H-pyrazole-4-carboxylic acid;
3-[[(trans-4-Methylcyclohexyl)carbonyl](1-methylethyl)amino]-1-{4-
[(phenylsulfonyl)amino]phenyl}-1H-pyrazole-4-carboxylic acid;
```

1-(4-Methyl-1-cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-1H-pyrazole-4-carboxylic acid;
1-(4,4-Dimethyl-1-cyclohexen-1-yl)-3-[[(trans-4-methylcyclohexyl)carbonyl](tetrahydro-3-furanyl)amino]-1H-pyrazole-4-carboxylic acid and salts, solvates and esters, and individual enantiomers thereof \_ where appropriate.

3. (currently amended) A method of treating or preventing viral infection which comprises administering to a subject in need thereof, an effective amount of at least one chemical entity chosen from compounds a compound of Formula (I)

wherein:

A represents hydroxy;

R¹ represents aryl, heteroaryl bonded through a ring carbon atom, or heterocyclyl bonded through a ring carbon atom, each of which may be optionally substituted by one or more substituents selected from  $-C_{1-6}$ alkyl, halo,  $-OR^A$ ,  $-SR^A$ ,  $-C(O)NR^BR^C$ ,  $-C(O)R^D$ ,  $-CO_2H$ ,  $-CO_2R^D$ ,  $-NR^BR^C$ ,  $-NR^EC(O)R^D$ ,  $-NR^ECO_2R^D$ ,  $-NR^EC(O)NR^FR^G$ ,  $-SO_2NR^FR^G$ ,  $-SO_2R^D$ , nitro, cyano,  $-CF_3$ ,  $-OCF_3$ ,  $NR^ESO_2R^D$ , phenyl and heterocyclyl, wherein the  $-C_{1-6}$ alkyl substituent itself may be optionally substituted by one or more substituents selected from  $-C_{5-9}$ cycloalkyl, halo,  $-NR^BR^C$ ,  $-C(O)NR^BR^C$ ,  $-NR^EC(O)R^D$ ,  $-SR^A$ ,  $-SO_2R^D$ ,  $OR^A$ , oxo, phenyl, heteroaryl or heterocyclyl; or  $R^1$  represents  $-C_{1-6}$ alkyl or  $-C_{5-9}$ cycloalkyl;

 $R^2$  represents phenyl substituted by one or more substituents selected from  $-C_{1-8}$  alkyl, halo,  $-OR^A$ ,  $-SR^A$ ,  $-C(O)NR^BR^C$ ,  $-C(O)R^D$ ,  $-CO_2H$ ,  $-CO_2R^D$ ,  $-NR^BR^C$ ,  $-NR^BC^C$ ,  $-NR^A$ 

 $-C(O)R^D$ ,  $-CO_2H$ ,  $-CO_2R^D$ ,  $-NR^BR^C$ ,  $-NR^EC(O)R^D$ ,  $-NR^ECO_2R^D$ ,  $-NR^EC(O)NR^FR^G$ ,  $-SO_2NR^FR^G$ ,  $-SO_2R^D$ , fluoro, nitro, cyano, oxo, and heterocyclyl, or wherein two substituents may together form a  $C_{1\cdot 2}$ alkylene bridge substituent;

t represents 0, 1, 2, 3 or 4;

n represents 0 or 1;

R³ represents heterocyclyl or heteroaryl; or phenyl optionally substituted by one or more substituents selected from -C<sub>1-6</sub>alkyl, halo, -OR<sup>A</sup>, -SR<sup>A</sup>, -C(O)NR<sup>B</sup>R<sup>C</sup>, -C(O)R<sup>D</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>D</sup>, -NR<sup>B</sup>C<sup>C</sup>, -NR<sup>E</sup>C(O)R<sup>D</sup>, -NR<sup>E</sup>CO<sub>2</sub>R<sup>D</sup>, -NR<sup>E</sup>C(O)NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>R<sup>D</sup>, nitro, cyano, and heterocyclyl; or R³ represents -C<sub>1-6</sub>alkyl optionally substituted by one or more substituents selected from -C<sub>1-6</sub>alkyl, -OR<sup>A</sup>, -SR<sup>A</sup>, -C(O)NR<sup>B</sup>R<sup>C</sup>, -C(O)R<sup>D</sup>, -CO<sub>2</sub>H, -CO<sub>2</sub>R<sup>D</sup>, -NR<sup>B</sup>R<sup>C</sup>, -NR<sup>E</sup>C(O)R<sup>D</sup>, -NR<sup>E</sup>CO<sub>2</sub>R<sup>D</sup>, -NR<sup>E</sup>C(O)NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>NR<sup>F</sup>R<sup>G</sup>, -SO<sub>2</sub>R<sup>D</sup>, fluoro, nitro, cyano, oxo, phenyl, heteroaryl and heterocyclyl;

R4 represents hydrogen;

R<sup>A</sup> represents hydrogen, -C<sub>1-6</sub>alkyl, arylalkyl, heteroarylalkyl, aryl, heterocyclyl or heteroaryl;

R<sup>6</sup> and R<sup>c</sup> independently represent hydrogen, -C<sub>1.6</sub>alkyl, aryl, heterocyclyl or heteroaryl; or R<sup>B</sup> and R<sup>C</sup> together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

 $R^D$  is selected from the group consisting of  $-C_{1-B}$ alkyl, aryl, heterocyclyl, heteroaryl, arylalkyl, and heteroarylalkyl;

R<sup>E</sup> represents hydrogen or -C<sub>1-6</sub>alkyl;

R<sup>F</sup> and R<sup>G</sup> are independently selected from the group consisting of hydrogen, -C<sub>1</sub>. <sub>6</sub>alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or R<sup>F</sup> and R<sup>G</sup> together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group;

and salts, solvates and esters or a pharmaceutically acceptable salt, solvate, or ester thereof.

- 4. (currently amended) A method as claimed in claim 3 which involves inhibiting HCV replication wherein the infection is an HCV infection.
- 5. (originally presented) A method as claimed in claim 3 in which the <del>chemical</del> entity <u>compound</u> is administered in an oral dosage form.
- Cancelled.
- 7. Cancelled.
- Cancelled.
- 9. (currently amended) A pharmaceutical formulation comprising at least one chemical entity chosen from compounds a compound of Formula (I) and pharmaceutically acceptable salts, solvates and esters or a pharmaceutically acceptable salt, solvate or ester thereof as defined in claim 1 in conjunction with at least one pharmaceutically acceptable diluent or carrier.
- (originally presented) A process for the preparation of a compound of Formula(I) as defined in claim 1, comprising treatment of a compound of Formula (II)

in which A is an alkoxy, benzyloxy or silyloxy group and R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined above for Formula (I) with a base.

- 11. (originally presented) A process as claimed in claim 10 in which A is ethoxy.
- 12. Cancelled.
- Cancelled.

- 14. (new) A pharmaceutical composition according to claim 9 in the form of a tablet or capsule.
- 15. (new) A pharmaceutical composition according to claim 9 in the form of a solution or suspension.